BioIndustry Ethics

Häftad, Engelska, 2005

AvDavid L. Finegold,Cecile M Bensimon,Abdallah S. Daar,Margaret L. Eaton,Beatrice Godard,Bartha Maria Knoppers,Jocelyn Mackie,Peter A. Singer

629 kr

Beställningsvara. Skickas inom 7-10 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

This book is the first systematic, detailed treatment of the approaches to ethical issues taken by biotech and pharmaceutical companies. The application of genetic/genomic technologies raises a whole spectrum of ethical questions affecting global health that must be addressed. Topics covered in this comprehensive survey include considerations for bioprospecting in transgenics, genomics, drug discovery, and nutrigenomics, as well as how to improve stakeholder relations, design ethical clinical trials, avoid conflicts of interest, and establish ethics advisory boards. The expert authors represent multiple disciplines including law, medicine, bioinformatics, pharmaceutics, business, and ethics.

Produktinformation

Utgivningsdatum2005-07-19
Mått152 x 229 x 25 mm
Vikt610 g
FormatHäftad
SpråkEngelska
Antal sidor382
FörlagElsevier Science Publishing Co Inc
ISBN9780123693709

Tillhör följande kategorier

Filosofiska discipliner inom Filosofi och religion

Chapter 1: INTRODUCTIONChapter 2: MERCK: STAYING THE COURSEChapter 3: GENZYME: PUTTING PATIENTS FIRSTChapter 4: MILLENNIUM PHARMACEUTICALS, INC.: CREATING AND SUSTAINING CORPORATE VALUESChapter 5: MAXIM PHARMACEUTICALS (A): INTERNAL AND EXTERNAL DIALOGUESChapter 6: DIVERSA INC.: ETHICAL ISSUES IN BIOPROSPECTING PARTNERSHIPSChapter 7: PIPELINE BIOTECH A/S: COMPETING REGULATORY REGIMES FOR LABORATORY ANIMAL EXPERIMENTSChapter 8: TGN BIOTECH: A START-UP WITH ETHICAL ROOTSChapter 9: INTERLEUKIN GENETICS AND ALTICOR: AN UNLIKELY PARTNERSHIPChapter 10: SCIONA LTD.: A PIONEER IN NUTRIGENOMICS: THE PATH TO CONSUMER ACCEPTANCEChapter 11: AFFYMETRIX, INC.: USING CORPORATE ETHICS ADVICEChapter 12: PHARMASNPS INC.: CREATING AN ETHICS ADVISORY BOARDChapter 13: MONSANTO COMPANY: BIO-AGRICULTURE PIONEERChapter 14: NOVO NORDISK: THE TRIPLE BOTTOM LINEChapter 15: CONCLUSION: LESSONS FOR COMPANIES AND FUTURE ISSUESINDEX